Top-down view of a glass petri dish filled with clear liquid droplets on a sage green background, with a glass pipette touching a droplet from the upper right

Image is for illustrative purposes only.

Peptides: Where Things Stand

Peptides are getting a lot of attention, and the rules around them are changing quickly. Here's a look at the current regulatory picture and what Evergreen is working on. Sign up for the latest news and offerings around peptides.

Evergreen's Peptide Program

Evergreen does not currently offer the below peptide therapies. We’re preparing a peptide program that will encompass the 6 peptides reviewed by the US Department of Health and Human Services on October 28, 2026, with every prescribing decision made by a licensed clinician.

  • Abstract illustration for BPC-157

    BPC-157

    Coming Soon

    A peptide researched for its potential to support recovery of tendons, ligaments, and muscles, and to protect the gut lining. Its clinical use in humans has not been established and remains under scientific and regulatory review.

  • Abstract illustration for Epitalon

    Epitalon

    Coming Soon

    A short-course peptide researched for healthy aging effects, including telomerase activity in cell studies, along with antioxidant effects and sleep–wake rhythm support. Its clinical use remains under scientific and regulatory review.

  • Abstract illustration for KPV

    KPV

    Coming Soon

    A topical KPV gel for localized application, researched for its inflammatory signaling pathways. It remains under scientific and regulatory review.

  • Abstract illustration for MOTS-c

    MOTS-c

    Coming Soon

    A naturally occurring mitochondrial-derived peptide researched for metabolic health, insulin sensitivity, and exercise mimetic effects. Its clinical use remains under scientific and regulatory review.

  • Abstract illustration for Semax

    Semax

    Coming Soon

    A nasal spray researched for mental performance, including focus, learning, and short-term memory. Its clinical use remains under scientific and regulatory review.

  • Abstract illustration for TB-500

    TB-500

    Coming Soon

    A peptide researched for its potential to support tendon, ligament, and muscle recovery by supporting cell movement and new small blood vessels in slow-healing tissue. Its clinical use remains under scientific and regulatory review.

Regulatory Update

Last updated:

What changed

On October 28, 2026, the U.S. Department of Health and Human Services announced an enforcement discretion policy covering six peptide ingredients: BPC-157, TB-500, Epitalon, Semax, KPV, and MOTS-C. Under it, the FDA intends to refrain from certain enforcement action against qualifying compounding pharmacies that prepare products containing these ingredients under specific conditions.

What this does and doesn't mean

These peptides are not FDA-approved, and enforcement discretion is not approval.

The policy applies only to qualifying 503A compounding pharmacies, only to the specified forms and routes of administration, and only to single-ingredient products.

Compounded products aren't FDA-reviewed for safety, effectiveness, or quality, and human clinical research on these peptides is limited.

The FDA can revise or withdraw the policy at any time, and we'll adjust accordingly.

Available Today

Currently Available

Evergreen Lean and Evergreen Longevity are currently open. Individual therapies may also be available after clinical review.

Available Today

Evergreen Lean

A clinician-guided weight management program with GLP-1 treatment options when prescribed after an independent medical evaluation.

View Evergreen Lean
Available Today

Evergreen Longevity

A clinician-guided healthy-aging program for weight maintenance, recovery, energy, and skin health. Protocol options may include microdose tirzepatide or semaglutide, Sermorelin, Glutathione, NAD+, or Low Dose Naltrexone (LDN), determined after an independent medical evaluation.

View Evergreen Longevity

NAD+ and Glutathione are available individually when clinically appropriate. The Evergreen Recovery program is not currently open. Sermorelin and Oxytocin may be available when clinically appropriate.

EDUCATIONAL REFERENCE · NOT CURRENTLY AVAILABLE

Other Peptides We're Monitoring

The peptides below are not currently available through Evergreen and are listed for educational reference only. Their regulatory status is under review.

Abstract illustration for GHK-Cu

GHK-Cu

Not Currently Available

A naturally occurring copper-binding tripeptide. It has been examined in laboratory research related to skin and tissue biology. Its clinical use remains under scientific and regulatory review.Note: GHK-Cu (Copper Peptide) is available as a topical as a part of the Evergreen Longevity program.

Regulatory status: Not currently available; regulatory status is under review.

Abstract illustration for CJC-1295 (No DAC)

CJC-1295 (No DAC)

Not Currently Available

A synthetic analog of growth hormone-releasing hormone (GHRH). It has been examined in endocrine research.

Regulatory status: Not currently available; regulatory status is under review.

Abstract illustration for Ipamorelin

Ipamorelin

Not Currently Available

A synthetic growth hormone secretagogue peptide. It has been examined in endocrine research.

Regulatory status: Not currently available; regulatory status is under review.

Abstract illustration for Selank

Selank

Not Currently Available

A synthetic peptide derived from a fragment of the immune protein tuftsin. It has been examined in research settings outside the United States.

Regulatory status: Not currently available; regulatory status is under review.

Abstract illustration for Thymosin Alpha-1

Thymosin Alpha-1

Not Currently Available

A synthetic version of a naturally occurring thymic peptide. It has been examined in immune-system research. Its clinical use remains under scientific and regulatory review.

Regulatory status: Not currently available; regulatory status is under review.

For Medications Currently Dispensed Through Evergreen

Pharmacy Quality & Clinical Oversight

These standards apply only to medications currently dispensed through Evergreen’s licensed partner pharmacy network. They do not describe the peptides described on this page.

USP <797>

Standards for sterile preparation followed for applicable medications currently dispensed through Evergreen

503A

Patient-specific medications compounded by licensed partner pharmacies when permitted and prescribed

Clinical oversight

An independent evaluation by a licensed clinician determines whether an available treatment is appropriate

  • Verified ingredients from FDA-registered manufacturers
  • Sterility and endotoxin testing on every sterile batch
  • Identity confirmation for every raw material lot
  • Validated potency and stability methods
  • Pharmacist review before every release

Compounded drugs are not reviewed or approved by FDA for safety, effectiveness, or quality.

Guided by Experts

Rigorous Peptide Education

Dr. Casey Greene, PharmD, IFMCP, is one of a select few pharmacists in the country to hold A4M Peptide Therapy Certification. He leads Evergreen’s education program, translating current peptide science and regulatory developments into clear learning content.

Educational content does not establish that a peptide is available, appropriate for an individual, or eligible for compounding.

Headshot of Dr. Casey Greene wearing a suit and tie
“Patients deserve clear information about regulatory status, licensed-clinician guidance, and pharmacy quality.”
Dr. Casey Greene, PharmD, IFMCP

Frequently Asked Questions

Peptides are short chains of amino acids that act as signaling molecules in the body. Different peptides have different biological roles, and their regulatory status, evidence, and potential medical use vary by substance. Inclusion on this page is educational and does not mean a peptide is available through Evergreen.

The regulatory status of peptides varies by substance. Whether a medication can be prescribed and compounded depends on multiple federal and state requirements, and those requirements can change over time. Evergreen only makes a treatment available when there is an appropriate pathway to do so and when a licensed clinician determines that treatment is appropriate for an individual patient.

Peptide availability is evaluated individually and depends on applicable federal and state requirements, pharmacy capabilities, and clinical review. Evergreen does not currently offer peptide therapies. See the regulatory update above for the current picture, and join peptide updates to hear from us if and when our peptide program becomes available.

No. Peptides and anabolic steroids are structurally and functionally different compounds. Peptides are chains of amino acids; steroids are a separate class of hormone-based compounds.

Certain peptide-based therapies, including GLP-1 therapies, are used in weight management. Evergreen Lean is currently available and requires an independent evaluation by a licensed clinician. The peptides described on this page are not currently available through Evergreen.

Medications currently offered through Evergreen are dispensed through licensed U.S. partner pharmacies when prescribed after an independent clinical evaluation. Availability depends on the medication, patient location, applicable requirements, and pharmacy capabilities.

This page is for educational purposes only and isn't medical advice. Compounded drug products are not FDA-approved. Evergreen does not currently offer the peptides described on this page.